Curezen Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
- Paid Up Capital ₹ 7.50 M
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.50 M
- Revenue Growth 14.06%
- Profit Growth 26.28%
- Ebitda 25.17%
- Net Worth 7.93%
- Total Assets 45.55%
About Curezen Pharma
Curezen Pharma Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 July 2016 (Eight years and seven months 17 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹2.50 M.
Madhumathi Kulkarni, Vani Kulkarni, and Raja Madaboina serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TG2016PTC110785
- Company No.
110785
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Curezen Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhumathi Kulkarni  | Director | 09-Jul-2016 | Current |
| Vani Kulkarni | Director | 09-Jul-2016 | Current |
| Raja Madaboina | Director | 09-Jul-2016 | Current |
Financial Performance of Curezen Pharma.
Curezen Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.06% increase. The company also saw a substantial improvement in profitability, with a 26.28% increase in profit. The company's net worth moved up by a moderate rise of 7.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curezen Pharma?
Unlock access to Curezen Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jan 2018 | City Union Bank Limited | ₹2.50 M | Open |
How Many Employees Work at Curezen Pharma?
Unlock and access historical data on people associated with Curezen Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curezen Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curezen Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.